首页> 外文期刊>Clinical and vaccine immunology: CVI >Pulsed-Field Gel Electrophoresis, Pertactin, Pertussis Toxin S1 Subunit Polymorphisms, and Surfaceome Analysis of Vaccine and Clinical Bordetella pertussis Strains
【24h】

Pulsed-Field Gel Electrophoresis, Pertactin, Pertussis Toxin S1 Subunit Polymorphisms, and Surfaceome Analysis of Vaccine and Clinical Bordetella pertussis Strains

机译:脉冲场凝胶电泳,百日咳杆菌粘附素,百日咳毒素S1亚基多态性以及疫苗和临床百日咳博德特氏菌菌株的表面组分析

获取原文
           

摘要

To add new insight to our previous work on the molecular epidemiology of Bordetella pertussis in Argentina, the prn and ptxS1 gene sequences and pulsed-field gel electrophoresis (PFGE) profiles of 57 clinical isolates obtained during two periods, 1969 to 1989 and 1997 to 2006, were analyzed. Non-vaccine-type ptxS1A was detected in isolates obtained since 1969. From 1989 on, a shift of predominance from the vaccine prn1 type to the nonvaccine prn2 type was observed. This was also reflected in a transition of PFGE group IV to group VI. These results show that nonvaccine B. pertussis strains are currently circulating. To analyze whether the observed genomic divergences between vaccine strains and clinical isolates have functional implications, protection assays using the intranasal mouse challenge model were performed. For such experiments, the clinical isolate B. pertussis 106 was selected as representative of circulating bacteria, since it came from the major group of the PFGE dendrogram (PFGE group VI). Groups of mice were immunized either with diphtheria-tetanus-whole-cell pertussis vaccine (ptxS1B prn1) or a vaccine prepared by us containing B. pertussis 106. Immunized mice were then challenged with a B. pertussis vaccine strain (Tohama, harboring ptxS1B and prn1) or the clinical isolate B. pertussis 106 (ptxS1A prn2). An adequate bacterial-elimination rate was observed only when mice were immunized and challenged with the same kind of strain. For further characterization, comparative proteomic profiling of enriched membrane proteins was done using three vaccine strains and the selected B. pertussis 106 clinical isolate. By matrix-assisted laser desorption ionization-time of flight mass spectrometry analysis, a total of 54 proteins were identified. This methodology allowed us to detect differing proteins among the four strains studied and, in particular, to distinguish the three vaccine strains from each other, as well as the vaccine strains from the clinical isolate. The differing proteins observed have cellular roles associated with amino acid and carbohydrate transport and metabolism. Some of them have been proposed as novel vaccine candidate proteins for other pathogens. Overall, the global strategy described here is presented as a good tool for the development of next-generation acellular vaccines.
机译:为我们以前对阿根廷百日咳博德特氏菌的分子流行病学, prn ptxS1 基因序列以及脉冲场凝胶的研究提供新的见解分析了两个时期(1969年至1989年以及1997年至2006年)获得的57株临床分离株的电泳图谱(PFGE)。在1969年以来获得的分离物中检测到非疫苗型 ptxS1A 。从1989年开始,疫苗的主要类型从 prn1 转变为非疫苗 prn2 类型。 PFGE第IV组向VI组的过渡也反映了这一点。这些结果表明非疫苗 B。百日咳菌株正在传播。为了分析观察到的疫苗株和临床分离株之间的基因组差异是否具有功能意义,使用鼻内小鼠攻击模型进行了保护性检测。对于这样的实验,临床分离株 B。百日咳菌 106被选为循环细菌的代表,因为它来自PFGE树状图的主要组(PFGE组VI)。用白喉-破伤风-全细胞百日咳疫苗( ptxS1B prn1 )或我们制备的含 B的疫苗对小鼠组进行免疫。百日咳106。然后用 B攻击免疫的小鼠。百日咳疫苗株(Tohama,带有 ptxS1B prn1 )或临床分离株 B。百日咳 106( ptxS1A prn2 )。仅当免疫小鼠并用相同菌株攻击后,才能观察到足够的细菌清除率。为了进一步表征,使用三种疫苗菌株和所选的 B进行了富集膜蛋白的蛋白质组比较分析。百日咳 106临床分离株。通过基质辅助激光解吸电离飞行时间质谱分析,总共鉴定出54种蛋白质。这种方法使我们能够在所研究的四种菌株之间检测不同的蛋白质,尤其是可以将三种疫苗菌株以及临床分离株中的疫苗菌株区分开。观察到的不同蛋白质具有与氨基酸,碳水化合物转运和代谢相关的细胞作用。已提出其中一些作为其他病原体的新型疫苗候选蛋白。总体而言,此处介绍的全球策略是开发下一代无细胞疫苗的良好工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号